The use of outcome measures meaningful to clinicians and health care consumers has important implications for the translation of trial data into logical clinical practice guidelines. Relevant measures of therapeutic effect in geriatric psychosis trials include reduction of psychotic symptoms and agitated behaviors, change in functional status and activities of daily living, and quality of life assessment. The impact of antipsychotic therapy on caregiver burden is especially meaningful, as it may have important implications and in recent years it has been evaluated as an important indicator of therapy effectiveness and long-term outcomes. Assessment of safety and tolerability parameters such as the liability for cardiovascular events, motor disturbances and fall risks, is especially important in trials targeting the frail geriatric patient population. This presentation will review the primary and secondary outcome measures used in clinical studies of available atypical antipsychotics for the treatment of psychosis associated with dementia. Safety and tolerability issues and their implications will be compared and discussed
Back to S108 Atypical Antipsychotic Drugs for the Treatment of Psychiatric Symptoms of Dementia: A New Look at Meaningful Outcomes
Back to Satellite Symposia
Back to The Eleventh International Congress